Sterling Biotech Limited Announces Audited Earnings Results for the Year Ended March 31, 2017

Sterling Biotech Limited manufactures gelatine and its derivatives, resinoids, glues, and allopathic pharmaceutical preparations. The Company manufactures Pharma Grade Gelatine and DiCalcium Phosphate, and other Pharma products. The Company manufactures gelatin from animal bones. It offers anticancer products, such as DOXO Rubicin, which is an anti-cancer chemotherapy drug and is classified as an anthracycline antibiotic; IDARUBICIN, which is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug; Daunorubicinis, which is used to treat acute lymphocytic and myelocyticleukemias; IMATINIB, which is a drug used to treat certain cancers, and EPI Rubicin, which is an anthracycline drug used for chemotherapy. Its other products include Lovastatin, which is a cholesterol-lowering agent; DACARBAZINE, which is used to treat Hodgkin disease and malignant melanoma, and Temozolamide, which is an oral alkylating agent used for the treatment of Grade IV astrocytoma.